News for Surmodics, Inc. (SRDX)

RoboMarkets has announced the addition of more than 1,160 new assets to its R StocksTrader platform, strengthening its position as a regulated multi-asset

On December 31, 2024, Barclays PLC executed a notable transaction by acquiring 950,308 shares of Surmodics Inc (SRDX) at a traded price of $39.6 per share. This

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the succ

Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SurModics (SRDX) delivered earnings and revenue surprises of 50% and 10.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Surmodics (SRDX) drops 5.8% as FTC reviews planned sale to GTCR, citing concerns about potential creation of dominating medical device coatings maker.

SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Shares of Surmodics (SRDX) fell 6% after reports of possible antitrust concerns about its planned sale to GTCR.

On January 2, 2025, Beryl Capital Management LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 6,359,570 shares of Revance Therapeutics Inc

SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

On November 25, 2024, Beryl Capital Management LLC (Trades, Portfolio) made a significant move by acquiring 4,500,000 shares of Brightcove Inc. This transaction

On November 11, 2024, Beryl Capital Management LLC (Trades, Portfolio) made a significant move by purchasing 900,000 shares of EMCORE Corp (NASDAQ: EMKR) at a p

Overview of the Recent Acquisition On October 29, 2024, Beryl Capital Management LLC (Trades, Portfolio) made a significant new investment in Profire Energy Inc

Biocompatible Coatings Industry size is expected to register 9.4% CAGR between 2024 and 2032 propelled by increasing demand in healthcare industry....

The biocompatible coating market is driven by increased demand in medical implants and devices for reduced rejection rates, alongside advancements in...